Dr. Peter Fitzgerald
Chief Medical Officer @ HeartBeam
San Francisco, United States
Dr. Peter Fitzgerald is a Series B investor at HeartBeam in San Francisco focused on Health Care and Medical Device. Dr. Peter Fitzgerald is Co-Founder and Managing Partner. He previously served as the Chief Medical Officer of HeartBeam. He previously worked at iXensor as an Advisor. Dr. Peter Fitzgerald is Director of the Center for Cardiovascular Technology at Stanford University Medical School. He is an Interventional Cardiologist and has a PhD in Engineering.He is Professor Emeritus in the Departments of Medicine and Engineering at Stanford.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Dr. Peter Fitzgerald invests in
Stages Dr. Peter Fitzgerald invests in
Countries Dr. Peter Fitzgerald invests in
Investment Focus
Industry
- Health Care 3 (50%)
- Medical Device 2 (33%)
- Health Diagnostics 2 (33%)
- Medical 1 (17%)
- Big Data 1 (17%)
Stage
- Series B 3 (50%)
- Series A 1 (17%)
Country
- United States 3 (50%)
- Israel 1 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Day Zero Diagnostics
|
The future of infectious disease diagnostics starts at Day Zero. By using whole-genome sequencing (WGS) and our proprietary enabling technologies, Day Zero is creating a new class of sequencing-based in-vitro diagnostics that generates clinically actionable data at scale. Our technologies include novel sample preparation methods enablingunprecedented ultra-high enrichment of pathogen DNA for sequencing directly from clinical samples, machine learning algorithms that provide clinically actionable diagnostic results, and a world-class database of WGS and drug efficacy profiles. Day Zero Diagnostics is on a mission to transform the way infectious disease diagnostics are performed by generating the stream of real-time sequencing data required to change how we track, manage and combat infectious diseases.With an enormous unmet clinical and economic need, we are targeting bloodstream infections and sepsis for our first application. The life expectancy of a patient with septic shock is 24 hours without fast effective antibiotic treatment. However, even when successful, current diagnostics take 2-5 days to identify the pathogen AND provide its antibiotic susceptibility profile. The lack of rapid, accurate, and comprehensive diagnostics, forces physicians to “carpet bomb” patients with severe infections with powerful, yet toxic, broad-spectrum antibiotics, which is not only ineffective in many cases but can also lead to significant morbidity and mortality. Day Zero delivers a complete diagnosis, including both the species and antibiotic resistance profile, in hours vs. days, enabling the physician to use a targeted treatment on day zero of hospital admission and resulting in better patient outcomes and cost savings. | $8.6M / Series A / Jan 23, 2019 | |
Genoox
|
Genoox develops and provides a cloud based big data platform for storing and managing genomic data. Its platform allows medical experts to provide genetic diagnostics and personalized treatments to their patients. Amir Trabelsi and Moshe Einhorn founded Genoox in 2014, with its headquarters in Palo Alto in California. | $6M / Series B / May 15, 2018 | |
CathWorks
|
CathWorks is a medical technology company focused on applying its advanced computational science platform to optimize PCI therapy decisions and elevate coronary angiography from visual assessment to an objective FFRangio based decision-making tool for physicians. FFR-guided PCI decision-making is proven to provide significant clinical benefits forpatients with coronary artery disease and economic benefits for patients and payers. The company’s focus is specifically on bringing the CathWorks FFRangio System to market to provide quick, precise, and objective intraprocedural FFRangio guidance that is practical for every case. | $15.8M / Series B / Oct 02, 2017 | |
|
CathWorks
|
CathWorks is a medical technology company focused on applying its advanced computational science platform to optimize PCI therapy decisions and elevate coronary angiography from visual assessment to an objective FFRangio based decision-making tool for physicians. FFR-guided PCI decision-making is proven to provide significant clinical benefits forpatients with coronary artery disease and economic benefits for patients and payers. The company’s focus is specifically on bringing the CathWorks FFRangio System to market to provide quick, precise, and objective intraprocedural FFRangio guidance that is practical for every case. | $15.8M / Series B / Oct 02, 2017 | |
ZingBox
|
ZingBox is a U.S.-based company that provides security for Internet of Things infrastructure. It is based in Mountain View, California. | $22M / Series B / Aug 17, 2017 | |
|
ZingBox
|
ZingBox is a U.S.-based company that provides security for Internet of Things infrastructure. It is based in Mountain View, California. | $22M / Series B / Aug 17, 2017 |
Co-Investors
About HeartBeam
HeartBeam is a cardiac technology company that has created the first and only 3D-vector electrocardiogram (VECG) platform for detecting heart attacks at any time and from any location.
HeartBeam Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Richa Gujarati
Senior Vice President, Product
|
|||
Alan Baumel
COO
|
|||
Branislav Vajdic
CEO & Founder
|
|||
Bryan Humbarger
Chief Commercial Officer
|
|||
Deborah Castillo
Vice President of Regulatory Affairs
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Dr. Peter Fitzgerald invest in?
Dr. Peter Fitzgerald invests primarily in Health Care, Medical Device and Health Diagnostics startups, most often at Series B and Series A stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Dr. Peter Fitzgerald last invest?
The most recent investment recorded for Dr. Peter Fitzgerald closed in Jan 2019. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
